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Abstract To determine feasibility of implementation of a
weight loss program for overweight Latinos with severe
mental illness. In this quasi-experimental study, a 14-week
behavioral weight loss course (extended) was implemented
at one clinic. A one-time nutrition class (brief) was given at
a sister clinic. Implementation feasibility was assessed by
consent and participation rates. Weight was followed for
6 months. Consent rates were high [77 % (49/64) extended;
68 % (39/57) brief], and 88 % (43/49) of extended subjects
participated and 88 % (38/43) completed follow-up.
Weight loss did not differ between groups. A behavioral
weight loss course is feasible to implement for this
population.
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Introduction
According to the Center for Disease Control, people with
severe and persistent mental illness (SMI) lose more than
25 years of potential life compared to the general popula-
tion, with cardiovascular disease (CVD) being the leading
cause of death (Colton and Manderscheid 2006). CVD risk
is increased by the metabolic syndrome, which is in turn
increased by obesity (National Cholesterol Education
Program [NCEP] 2001). The National Health and Nutrition
Examination Survey (NHANES) indicates that approxi-
mately 25 % of the US adult population has the metabolic
syndrome, with Latinos at the greatest risk of any ethnic
group (Park et al. 2003). Several studies have found that
people with SMI are at high risk for the metabolic syn-
drome and CVD (Newcomer and Hennekens 2007;
Davidson et al. 2001; Lambert et al. 2003). The Clinical
Antipsychotic Trials of Intervention Effectiveness (CA-
TIE) Schizophrenia Trial found that the metabolic syn-
drome was twice as prevalent among individuals with
schizophrenia compared to age-matched NHANES general
populations (McEvoy et al. 2005). Outpatients with SMI
also have higher odds of having obesity, with women at
particularly high risk (McEvoy et al. 2005; Allison et al.
2009; Daumit et al. 2003).
Treatment with certain antipsychotic medications can
contribute to increased metabolic risk (Allison et al. 1999;
Newcomer 2005). Despite several metabolic screening
guidelines for people with SMI taking antipsychotic med-
ications (Marder et al. 2004; Parks et al. 2008), actual
screening and treatment continues to be alarmingly low
(Morrato et al. 2008; Essock et al. 2009; Haupt et al. 2009;
Nasrallah et al. 2006). Part of the problem is limited
information available to guide mental health clinicians on
strategies to lower cardiovascular risk (Amiel et al. 2008).
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The Schizophrenia Patient Outcomes Research Team
(PORT) recently reviewed the body of evidence available
and recommended that overweight or obese individuals
with schizophrenia should be offered a psychosocial weight
loss intervention at least 3 months in duration (Dixon et al.
2010).
Unfortunately, there is a paucity of information about
weight loss programs for minorities with SMI, particularly
Latinos (Cabassa et al. 2010). According to a recent liter-
ature review, among weight loss studies reporting racial/
ethnic composition of people with SMI, only 6 % of the
subjects were Latino (45/776) and only one case report of 8
subjects included non-English-speaking participants (Ca-
bassa et al. 2010). This lack of data is worrisome since
urban Latinos with SMI have an even higher prevalence of
obesity and metabolic syndrome than people with SMI in
CATIE or among Latinos in general in NHANES (Hel-
lerstein et al. 2007; Kato et al. 2004). Given the substan-
dard health care received by minorities and SMI, and the
rapid growth of the US Latino population, this lack of data
on a highly vulnerable population is particularly concern-
ing (Smedley et al. 2003; Alegria et al. 2008).
Our group began to address this problem by adapting a
weight loss program for Latinos with SMI. Ganguli and
colleagues at the University of Pittsburgh implemented a
14-week, behavioral therapy course for overweight outpa-
tients with schizophrenia spectrum disorders; and more
subjects in the weight-loss intervention group lost C5 % of
their body weight than controls (Brar et al. 2005). We
selected this intervention because it was manualized,
inexpensive, and targeted outpatients. This course also met
key PORT elements of weight loss interventions (e.g.,
portion control, goal setting, weigh-ins). These cultural
adaptations have been described previously (Mangurian
et al. 2009). Briefly, modifications for this urban, Latino
SMI population included Spanish translation, incorporation
of traditional Dominican food (e.g., plantains, rice and
beans); incorporation of culturally-informed exercises
activities (e.g., merengue); incorporation of cultural values
(e.g., family); and removal of references less relevant for
inner city populations of low socio-economic status (e.g.,
ownership of car). These modifications are consistent with
recommended cultural adaptations to weight loss inter-
ventions for non-SMI populations (Mier et al. 2009).
Although switching antipsychotic medications can be
effective for weight reduction in SMI populations (New-
comer et al. 2008; Weiden et al. 2008), a weight loss
program was chosen because of data indicating that Latinos
with SMI prefer behavioral techniques over medication
changes for antipsychotic-induced metabolic problems
(Mangurian et al. 2010).
In this quasi-experimental pilot study, we examined the
feasibility of implementation of a culturally-modified
behavioral intervention for overweight and obese Latino
outpatients with SMI. We hypothesized that the course
could be feasibly delivered in a community mental health




This study was conducted at the two outpatient clinics of
the Washington Heights Community Service (WHCS). The
WHCS clinics are part of the New York State Office of
Mental Health and provide mental health services to people
with SMI living in Northern Manhattan. The clinics are
similar demographically with an ethnic distribution of 75
% Hispanic, 15 % African American, 9 % Caucasian, and 1
% Asian (Hellerstein et al. 2007).
Study Subjects
As part of a quality improvement initiative, all adults
attending the WHCS continuing day treatment program
(CDTP) were weighed in September 2007. WHCS psy-
chiatrists referred potential study subjects with
BMI C 25 kg/m2 to the research team for possible inclu-
sion in the weight loss program offered at their clinic.
Study inclusion criteria were: (1) BMI C 25 kg/m2, (2)
WHCS CDTP patient status, and (3) age C 18. Exclusion
criteria included: (1) inability to provide informed consent
or (2) having a health condition preventing light exercise.
Subjects received compensation for initial screening ($10)
and each follow-up assessment ($5), independent of
attendance in course.
The mean age of the study population was 60.5 years
(SD 13.3y). The population was predominantly female (64
%, 51/80). Regarding race/ethnicity, 85 % (68/80) were
Latino, 11 % (9/80) African American, and 4 % (3/80)
Caucasian. Most of the Latinos were of Dominican descent
(79 %, 54/68). In regard to language capacity, 59 % (47/80)
were monolingual Spanish-speakers, 24 % (19/80) bilin-
gual, and 18 % (14/80) monolingual English-speaking.
Forty-one percent (33/80) were never married, 36 % (29/
80) were separated or divorced, 10 % (8/8) widowed, and
13 % (10/80) married. In regard to education, 40 % (32/80)
had less than or equal to 8th grade education, 25 % (20/80)
completed some high school, 16 % (13/80) were high
school graduates, 11 % (9/80) completed some college, 6
% (5/80) completed college, and 1 % (1/80) unknown.
Only 6 % had an annual income ranging from $18,000 to
$35,999, with most not knowing their income status (53 %,
42/80) or making less than $18,000 yearly (41 %, 33/80).
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The majority of the population was disabled (66 %, 53/80)
or unemployed (15 %, 12/80). Regarding Axis I diagnosis,
61 % (49/80) had schizophrenia spectrum disorders, 20 %
(16/80) had major depressive disorder, 11 % (9/80) had
bipolar disorder, with the remaining 8 % (6/80) having a
variety of other diagnosis. The mean baseline BMI was
33.59 (0SD 5.95). In summary, the study population was
predominantly Latino of Dominican descent, Spanish-
speaking, low-income, single, had less than a high school
education, obese and carried a diagnosis of schizophrenia-
spectrum disorder. There were no differences in these
demographic or diagnostic categories between the two
comparison groups.
Study Design
This was a quasi-experimental pilot study in which subjects
received different intensity of interventions dependent
upon the clinic they attended. Subjects were not random-
ized to intervention groups for feasibility reasons. One
clinic received the ‘‘Brief Intervention’’ and the sister clinic
received the ‘‘Extended Intervention’’ as described below.
Because of clinic space and programming constraints,
subjects in the extended intervention group were divided
into three groups of approximately 15 subjects based upon
date of consent for participation and language spoken. Two
groups ran from March to June 2008; one group was
bilingual and the other was only conducted in Spanish. The
third bilingual group was conducted from July to Sep-
tember 2008.
Description of Interventions
There were two intervention groups: (1) the extended
intervention and (2) the brief intervention. The extended
intervention was a culturally-modified, behavioral therapy
course based on the Ganguli protocol (Brar et al. 2005).
The culturally-modified course was taught by a bilingual,
registered dietitian. The course was comprised of 20 clas-
ses over 14 weeks, using a treatment manual (Mangurian
et al. 2007). All participants were provided with a manual
in their preferred language. Classes were initially twice-
weekly for 60-min (week 1-6) and then once weekly
(weeks 7-14). Each class consisted of a weigh-in and an
assessment of number of footsteps taken daily since the
prior session (the personal pedometer stored daily record-
ings for up to 1 week). These values were documented on a
bulletin board in the classroom. Following these assess-
ments, an instructional phase (e.g., incorporating exercise
into daily routine) was conducted. Each class also had an
individual review phase and an exercise component (e.g.,
15 min walking in place). Healthy and inexpensive snacks
were purchased at a local grocer and provided by the
instructor at each class, with the cost per serving, serving
size, and pertinent nutrition facts discussed. A WHCS staff
nurse sat in on the course to be trained to teach it in the
future at no additional expense.
The brief intervention was a one-time 45-min nutrition
class taught by the WHCS inpatient registered dietician and
all subjects were provided with a one-page bilingual
handout of information on healthy eating habits. Subjects at
both sites received a personal scale (either TANITA BP-
630 W or Healthometer 845 KL) and a personal pedometer
(OMRON HJ-112 Premium Pedometer with Calorie
Counter).
Measures
Because small pilot studies often lack power to detect main
effects (Kraemer 2005), we constructed this pilot study to
determine the feasibility of implementing a culturally-
modified weight loss program for a high-risk Latino pop-
ulation with SMI. As an indicator of feasibility, consent
and participation rates were collected for both groups.
Participation was defined as attending at least one class in
the course. Class attendance and use of pedometers were
other indicators of feasibility and acceptability.
We also evaluated the feasibility of collecting secondary
outcome measures described below at baseline, 14-, 26-,
and 40-weeks. Secondary outcome measures were weight
(and calculated BMI), ATP III criteria for the metabolic
syndrome (waist circumference, blood pressure, fasting
glucose and fasting lipids). Subjects were also asked to
complete a health status questionnaire (SF-12) (Ware et al.
1996); and a Client Satisfaction Questionnaire (Attkisson
and Zwick 1982; Roberts and Attkisson 1983). For logistic
purposes, all outcome measures were collected 2 weeks
prior and after the exact follow-up date. Feasibility to
collect these secondary outcome measures was determined
by the percentage of collection of these variables. Common
problems encountered while collecting these measures
were described.
At baseline, subjects completed a brief survey, provid-
ing basic demographic information. Psychiatric diagnoses
and all medications were collected from the medical chart.
Because considerable evidence indicates that some anti-
psychotic medications can worsen obesity and metabolic
syndrome parameters (Lieberman et al. 2005; Casey 2005),
changes in psychotropic medication prescription during the
intervention could impact weight loss. To evaluate this
potential confounder, psychotropic medication history was
collected at each of the time points and past psychotropic
medication history up to 1 year prior was collected from
the medical chart. Based on prior research of chronic, non-
medication naive subjects (Allison et al. 1999; Newcomer
2005; Marder et al. 2004; Baptista et al. 2002),
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antipsychotic medications were divided into three types
dependent on weight-promoting potential: (1) High (clo-
zapine, olanzapine, chlorpromazine, thioridizine); (2)
Medium (risperidone, quetapine, palperidone, perphena-
zine, loxapine); and (3) low (aripiprazole, ziprasidone,
molindone, haloperidol, fluphenazine, pimozide, thiothix-
ine, trifluoperazine). Given the practice of polypharmacy,
subjects were divided into four groups: (1) Taking at least
one high-weight promoting antipsychotic medication,
(2) taking at least one medium-weight promoting antipsy-
chotic medication, (3) taking only a low-weight promoting
antipsychotic medication, (4) taking no antipsychotic
medication.
Data Analysis
Chi-Squared analysis was used to determine differences
between the two samples including demographic vari-
ables, weight gain liability of antipsychotic medication
prescribed, and prevalence of ATP-III-defined metabolic
syndrome. An independent samples t test was done to
determine differences in age, weight and BMI between
the two clinic samples. Feasibility of course implemen-
tation was characterized by comparing consent and par-
ticipation rates to those from another weight loss program
involving non-Latino subjects with SMI (Kalarchian et al.
2005). Feasibility of collection of secondary outcome
measures was also characterized. Chi-Squared analysis
was used to examine the relationship between weight loss
and intervention program at the two follow-up time
points.
Written informed consent was obtained from partici-
pants (New York State Psychiatric Institute/Columbia
University Department of Psychiatry Institutional Review
Board Protocol #5575). Some of the authors have received
grant/research support from pharmaceutical industries.
Given that this was an entirely behavioral intervention and
that subjects were selected irrespective of their antipsy-
chotic regimen, it is improbable that this support indicates
a conflict of interest for this study. All authors certify
responsibility for this publication.
Results
Feasibility of Implementation of the Weight Loss
Course
Of the patients served at the extended intervention clinic,
89 % (64/72) were eligible to participate. Seventy-two
percent (57/79) of the patients served at the brief inter-
vention clinic were eligible to participate. Consent rates
were high, with 77 % (49/64) of subjects consenting to
participate in the extended intervention clinic and 68 %
(39/57) at the brief intervention clinic. Eighty-eight percent
(43/49) of consenting subjects in the extended intervention
participated in the 14 week course, and 95 % (37/39) of
consenting subjects participated in the one-time brief
intervention. Consent and participation rates for the
extended intervention were comparable or higher than
another 3-month behavioral weight loss intervention
developed for non-Latino SMI populations (73 % con-
senting; 77 % participating) (Kalarchian et al. 2005). Of
extended intervention participants, 68 % (28/43) attended
over half of the classes, with mean course attendance being
12.71 (SD 4.99) of the 20 classes. Equipment was used
regularly as evidenced by 63 % (27/43) of extended
intervention subjects wearing pedometers at least 50 % of
the time during the study.
Secondary outcome measures were collected in 88 %
(38/43) of participants in the extended intervention and 78
% (29/37) in the brief intervention at all follow-up time
points up to 6 months. These follow-up rates were com-
parable to the 83 % rate of another 3-month behavioral
weight loss intervention developed for non-Latino SMI
populations (Kalarchian et al. 2005).
Although it was feasible to collect secondary outcome
measures in this population, there were unexpected chal-
lenges, including: (1) subject reluctance to have waist
circumference measured depending on the person collect-
ing the measure; (2) subjects were reluctant to have labs
drawn; (3) staff were reluctant to have increased work load
of additional laboratory draws; (4) staff were reluctant to
have frequent laboratory screening because of limited pri-
mary care resources; and (5) the study mobile scale was
stolen in one of the clinics.
Change in Body Weight
There were no significant differences between the two
intervention groups in mean weight or BMI weights at any
follow-up time point. There was also no significant dif-
ference in the proportion of subjects that lost or maintained
weight between the two interventions at all of the follow-
up time points.
Although not statistically significant, there was a mean
raw weight loss at 40-weeks in the brief intervention group
(from 205.7lbs SD40.0lbs to 202.5lbs SD39.2lbs) that was
primarily due to a subpopulation of that group (24 %; 7/29)
who lost C5 % of their body weight. These subjects were
predominantly women (86 %, 6/7), but otherwise there was
a range in education, income, language, marital status,
medications, and diagnosis. Informal interviews of these
subjects revealed that researcher staff regularly checking
their weight in the clinic was very helpful.
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Consumer Satisfaction and Self-Reported Health
Of the subjects participating in the extended intervention,
the mean score on the Client Satisfaction Questionnaire
(CSQ) was 28.6 (SD = 2.8). This reflects high satisfaction
with the weight loss course since CSQ-8 scores range from
8 to 32, with higher values indicating higher satisfaction.
Subjects’ perceptions of their overall health and emotional
health were assessed using the global health scale from the
SF-12. On a scale that ranges from 0 (poor health) to 4
(excellent) health, subjects generally reported fair to good
health and emotional health, with all subjects showing
improvements between baseline and follow-up (health ?.
21, p = 0.06, emotional health ?0.35, p \ 0.01). The
intervention groups did not differ in terms of health or
emotional health.
Development of a Maintenance Class
Because of consumer desire, a weekly maintenance class
developed organically in the clinic after the weight-loss
course ended. The maintenance course is co-led by a peer
educator, with weekly recordings of weights and pedome-
ter readings, and is based on the culturally-modified man-
ual monthly, 6 months after course completion, 60 % (26/
43) of extended intervention subjects attended at least one
maintenance class; and 30 % (13/43) attended over five
maintenance classes. Two years after course completion,
23 % (10/43) of the original participants attend regularly.
Half of those subjects (5/10) have lost weight. The course
is viewed as a huge success in the clinic and continues to
address cultural aspects of Latino foods and community
resources such as local farmers’ markets.
Study Sample Antipsychotic Medications
There were significant differences between clinics in terms
of weight gain liability of antipsychotic medications pre-
scribed at baseline, with 72 % (31/43) of extended inter-
vention subjects being prescribed at least one medium or
high weight-promoting antipsychotic medication compared
with 43 % (16/37) of the brief intervention subjects
(p \ 0.004).
Medication changes during the study and up to 1 year
prior were also evaluated and there were no significant
differences. In the extended intervention group, 71 % (27/
38) stayed on the same medication, 11 % (4/38) changed to
a medication that could help them lose weight, and 18 %
(7/38) switched to a medication that could make them gain
weight. In the brief intervention, 72 % (21/29) stayed on
the same medications, 17 % (5/29) changed to a medication
that could help them lose weight, and 10 % (3/29) switched
to a medication that could make them gain weight over this
same time period.
Discussion
This pilot study provides evidence that a culturally-modi-
fied, 14-week behavioral weight loss course for a pre-
dominantly Latino SMI population is promising given
feasibility of implementation and acceptability to con-
sumers. We know of no other prior study evaluating
implementation of a behavioral weight loss treatment
program for this high risk, predominantly Spanish-speak-
ing, Latino SMI population.
Feasibility of Implementation of the
Culturally-Modified Weight Loss Course
The high consent and participation rates demonstrate that
this culturally-modified behavioral weight loss course is
feasible to implement in a community setting. High course
attendance rates and the development of a maintenance
class at the request of the consumers indicate considerable
acceptability of the program and a desire by these pre-
dominantly Latino consumers to address their weight
problems. The feasibility and acceptability of this inter-
vention are particularly important given PORT recom-
mendations for weight loss programs for people with SMI
and the lack of culturally-tailored weight-loss programs
developed for this high-risk ethnic population with limited
English proficiency (Dixon et al. 2010; Cabassa et al.
2010).
Also notably, it was feasible to collect labs in this high
risk community outpatient sample. Given the alarmingly
low screening rates of SMI outpatients despite national
recommendations (Morrato et al. 2008; Essock et al. 2009;
Haupt et al. 2009), and the high rates of weight problems
among this Latino population (80 %, 121/151), community
mental health administrators should strongly consider
mandating at least annual metabolic screening in these
high-risk SMI populations that they serve.
Efficacy of Culturally-Modified Weight Loss Course
Despite considerable subject engagement in the course,
there was a lack of substantial weight loss as a result of this
culturally-modified behavioral weight loss program. There
are several possible explanations for this finding. First, the
limitation of the quasi-experimental study design resulted
in notable prescription differences between the two cohorts
with significantly more extended intervention subjects
being prescribed at least one medium or high weight-
promoting antipsychotic medication (e.g., olanzapine,
154 Community Ment Health J (2013) 49:150–156
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quetiapine) compared those subjects in the brief interven-
tion. These prescription differences may have caused more
weight gain in the extended intervention and might explain
the disappointing weight loss findings. Even without the
study design limitations, small pilot studies often lack
power to detect main effects (Kraemer 2005). Given that
weight loss was confounded by significant differences in
psychotropic medication prescription, a larger, randomized
controlled trial should be done to more accurately assess
course impact on weight loss. In addition, since this study
was conducted with a predominantly Dominican popula-
tion, future studies should be done in other Latino sub-
populations to determine what similarities and differences
exist.
We were surprised to find that almost one quarter of the
brief intervention subjects who completed follow-up
assessments lost C5 % of their body weight, and main-
tained this loss for 6 months. These subjects considered
frequent weight checks by research staff to play an
important role in this weight loss. It is reasonable to con-
sider that a minimal and inexpensive intervention (e.g.,
receiving a scale) along with frequent monitoring of weight
is useful for a subgroup of participants.
Limitations
The limitations of this pilot study provide useful informa-
tion for the development of future studies. As described
above, the main limitation is related to the quasi-experi-
mental study design which resulted in significant differ-
ences in weight gain liability of antipsychotic medications
prescribed at baseline between the two groups. Second,
there was a bimodal distribution of weight loss, particularly
in the brief-intervention group, which made certain statis-
tical analysis (e.g., propensity-score matching) unfeasible.
Third, this pilot study made an assumption that orders
written in the chart indicated medication adherence, but
adherence rates are low in this SMI population (Weiden
2007). Also, adherence may vary in Latino populations
dependent on primary language spoken, and this was not
controlled for (Gilmer et al. 2009). Adherence is note-
worthy because non-adherence to a high weight-promoting
medication could lead to weight loss and impact results.
In summary, clinicians should consider behavioral
interventions for Latino SMI populations, as this Domini-
can Latino population was very interested and willing to
attend this course. Given the high rate of obesity among
this Latino population with SMI and low metabolic
screening rates of SMI outpatients in general (Morrato
et al. 2008; Essock et al. 2009; Haupt et al. 2009), public
health agencies should encourage regular screening and
treatment of this high-risk population.
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